CNBC Television·2025-10-30 22:20Market Dynamics & Competition - Eli Lilly's stock surged almost 4% following a strong earnings report driven by high demand for its GLP-1 drugs, Zepbound and Mounjaro [1] - Novo Nordisk's stock decreased by 25% after confirming an unsolicited bid to acquire Metsera, surpassing Pfizer's previous offer [1] - Pfizer is reportedly considering a lawsuit against Novo Nordisk and Metsera regarding the acquisition bid [2] - The pharmaceutical industry rarely sees overbidding scenarios like Novo Nordisk's attempt to acquire Metsera [5] - Metsera previously declined Novo Nordisk's offer due to doubts about deal approval, but is now reconsidering [6] Company Performance & Strategy - Eli Lilly's guidance was raised by $2 billion, indicating strong confidence with only two months remaining in the year [4] - Eli Lilly's revenue reached $17 billion, with Mounjaro and Zepbound contributing $10 billion [9] - Novo Nordisk's aggressive pursuit of Metsera suggests a degree of desperation to revitalize its business, especially considering pipeline setbacks [4] - A former head of R&D at Pfizer is expected to join Novo Nordisk's board, potentially influencing the Metsera deal [7] Regulatory & Pricing Pressures - GLP-1 drugs are under scrutiny from the administration regarding drug pricing [10] - Prices for GLP-1 drugs have decreased by 50% within a year, from approximately $1,200 per month to $400-$500 [10] Potential Acquisition Targets - Amylin, with a clinic launch anticipated in the coming months, holds potential value [11] - Viking remains a possible acquisition target, but requires significant investment in manufacturing infrastructure [12]